Geneva Capital Management LLC Buys 7,958 Shares of Repligen Corporation (NASDAQ:RGEN)

Geneva Capital Management LLC grew its stake in Repligen Corporation (NASDAQ:RGEN) by 5.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 143,543 shares of the biotechnology company’s stock after acquiring an additional 7,958 shares during the quarter. Geneva Capital Management LLC owned 0.26% of Repligen worth $18,264,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in RGEN. Price T Rowe Associates Inc. MD boosted its holdings in Repligen by 11.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock worth $1,027,165,000 after acquiring an additional 743,815 shares in the last quarter. Point72 Asset Management L.P. raised its stake in shares of Repligen by 183.1% in the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock worth $132,227,000 after purchasing an additional 594,189 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in shares of Repligen in the fourth quarter worth $53,428,000. Raymond James Financial Inc. purchased a new position in shares of Repligen in the fourth quarter worth $52,492,000. Finally, Marshall Wace LLP raised its stake in shares of Repligen by 73.8% in the fourth quarter. Marshall Wace LLP now owns 412,235 shares of the biotechnology company’s stock worth $59,337,000 after purchasing an additional 175,013 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

RGEN has been the subject of several recent analyst reports. Barclays initiated coverage on Repligen in a research note on Tuesday, June 24th. They issued an “overweight” rating and a $150.00 price target for the company. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research note on Sunday, June 29th. Evercore ISI reduced their price objective on Repligen from $140.00 to $130.00 and set an “in-line” rating for the company in a research report on Tuesday, July 8th. Canaccord Genuity Group reduced their price objective on Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a research report on Wednesday, April 16th. Finally, Royal Bank Of Canada upped their price objective on Repligen from $193.00 to $204.00 and gave the company an “outperform” rating in a research report on Wednesday, July 30th. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $169.45.

Repligen Stock Performance

NASDAQ RGEN opened at $118.91 on Monday. The firm has a market cap of $6.68 billion, a price-to-earnings ratio of -475.62, a price-to-earnings-growth ratio of 2.19 and a beta of 1.05. The company has a quick ratio of 5.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.27. The business has a 50-day moving average price of $123.41 and a 200-day moving average price of $136.09. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $182.52.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). The business had revenue of $182.37 million during the quarter, compared to the consensus estimate of $174.62 million. Repligen had a positive return on equity of 4.65% and a negative net margin of 2.05%. The business’s revenue was up 14.8% on a year-over-year basis. During the same period last year, the company earned $0.40 EPS. As a group, equities research analysts predict that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.